Pharmacokinetics and Mechanism of Intestinal Absorption of JBP485 in Rats

被引:28
作者
Cang, Jian [1 ]
Zhang, Jian [1 ]
Wang, Changyuan [1 ]
Liu, Qi [1 ]
Meng, Qiang [1 ]
Wang, Desheng [2 ]
Sugiyama, Yuichi [2 ]
Tsuji, Akira [3 ]
Kaku, Taiichi [4 ]
Liu, Kexin [1 ]
机构
[1] Dalian Med Univ, Dept Clin Pharmacol, Coll Pharm, 9 W Sect,Lvshun S Rd, Dalian 116044, Peoples R China
[2] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan
[3] Kanazawa Univ, Fac Pharmaceut Sci, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 920, Japan
[4] Japan Bioprod Ind Co Ltd, Tokyo, Japan
基金
中国国家自然科学基金;
关键词
JBP485; dipeptide; PEPT1; Glycylsarcosine; Pharmacokinetics; H+/PEPTIDE SYMPORTER PEPT1; TRANSPORT; CACO-2; AFFINITY;
D O I
10.2133/dmpk.DMPK-10-RG-045
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
To investigate the pharmacokinetics and mechanism of intestinal absorption of JBP485 in rats, the pharmacokinetics of JBP485 were investigated in vivo both intravenously and orally The effects of glycylsarcosine (Gly-Sar) on the uptake and transepithelial transport of JBP485 were examined in everted intestinal sacs, in situ jejunal perfusion. Caco-2 cells and PEPT1 transfected He la cells. The gastrointestinal absorption of JBP485 was rapid T-1/2 beta was 2 25 +/- 0 06 h. CLplasma was 2 99 +/- 0 002 ml/min/kg, V-d was 0 22 +/- 0 05 l/kg and bioavailability was about 30% at a dosage of 25 mg/kg JBP485 underwent rapid distribution in the tissues Gly-Sar significantly decreased JBP485 uptake and transport in these models. A kinetic study showed that JBP485 was transported by PEPT1 in Caco-2 cells with Km and Vmax values of 0 33 +/- 0 13 mM and 0 72 +/- 0 06 nmol/mg protein/10 min, respectively JBP485 appeared to have linear pharmacokinetics at intravenous doses of 6 25-100 mg/kg with minor first-pass effect, and JBP485 was mainly distributed in the kidney, JBP485 is a substrate for PEPT1 which is involved in the absorption of JBP485 in rat intestine.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 23 条
[1]
The renal type H+/peptide symporter PEPT2:: structure-affinity relationships [J].
Biegel, A. ;
Knuetter, I. ;
Hartrodt, B. ;
Gebauer, S. ;
Theis, S. ;
Luckner, P. ;
Kottra, G. ;
Rastetter, M. ;
Zebisch, K. ;
Thondorf, I. ;
Daniel, H. ;
Neubert, K. ;
Brandsch, M. .
AMINO ACIDS, 2006, 31 (02) :137-156
[2]
The intestinal H+/peptide symporter PEPT1:: structure-affinity relationships [J].
Brandsch, M ;
Knütter, I ;
Leibach, FH .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (01) :53-60
[3]
Intestinal transport of β-lactam antibiotics:: Analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux [J].
Bretschneider, B ;
Brandsch, M ;
Neubert, R .
PHARMACEUTICAL RESEARCH, 1999, 16 (01) :55-61
[4]
Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1 [J].
Brodin, B ;
Nielsen, CU ;
Steffansen, B ;
Frokjær, S .
PHARMACOLOGY & TOXICOLOGY, 2002, 90 (06) :285-296
[5]
The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology [J].
Daniel, H ;
Kottra, G .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 447 (05) :610-618
[6]
The role of transporters in drug interactions [J].
Endres, CJ ;
Hsiao, P ;
Chung, FS ;
Unadkat, JD .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (05) :501-517
[7]
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736
[8]
Liu KX, 2000, J PHARMACOL EXP THER, V294, P510
[9]
Liu KX, 1995, CLIN PHARMACOL THER, V5, P2187
[10]
Nakanishi T, 2000, INT J CANCER, V88, P274, DOI 10.1002/1097-0215(20001015)88:2<274::AID-IJC20>3.3.CO